In recent years, few drugs have made as much noise in the world of medicine—and pop culture—as semaglutide, marketed under names like Ozempic and Wegovy. Once reserved for the treatment of type 2 diabetes, these medications are now at the center of a dramatic shift in how doctors—and patients—approach obesity and weight management. From celebrity endorsements to social media trends, semaglutide has become a household name, sparking hope for millions struggling with weight and drawing concerns about overuse, shortages, and potential risks.
Obesity, a chronic disease affecting more than 40% of U.S. adults, is linked to increased risk of heart disease, diabetes, cancer, and premature death. Traditional approaches—diet, exercise, behavioral therapy—have had limited long-term success for many. Enter Ozempic and its cousin Wegovy: injectable medications that promise significant, sustained weight loss. But are they a panacea, or another fleeting trend?
Let’s explore the science, dispel myths, and offer practical advice for navigating this new era in obesity management.
